Abbreviations {#cenomen10}
=============

ACQ

:   Asthma Control Questionnaire

CCQ

:   common cold questionnaire

IQR

:   interquartile range

IRR

:   incidence rate ratio

MAP

:   Managing Asthma in Pregnancy

PCR

:   polymerase chain reaction

RR

:   relative risk

Pregnant women, especially those with asthma, experience significant problems associated with respiratory viral infections.[@bib1] The outcomes from pandemic 2009 influenza A(H1N1) were more severe in pregnant women and people with asthma,[@bib2] and retrospective studies report more infections in pregnant women with asthma than those without asthma.[@bib3], [@bib4] The effects of viral infection may be more severe among pregnant women with asthma, with a 10-fold increased risk of respiratory-related hospitalization during the influenza season described for pregnant women with asthma compared with women without asthma.[@bib1] Respiratory viral infections are reported to be a significant cause of asthma exacerbations during pregnancy[@bib5] and may be associated with adverse outcomes, such as low birth weight.[@bib6]

The characteristics and mechanisms of these effects are not well understood. Among nonpregnant women with asthma, susceptibility to respiratory viral infection is not increased, but colds are more severe with more lower respiratory tract symptoms, which are longer lasting.[@bib7] However, pregnant women may be more susceptible to viral infection because of a pregnancy-related impairment in antiviral interferon responses[@bib8], [@bib9] or deficiencies in epithelial cell function, overproduction of mucus, or alveolar macrophage dysfunction.[@bib10]

We hypothesized that during pregnancy, women with asthma experience more frequent and more severe respiratory viral infections than pregnant women without asthma. We assessed these effects prospectively during pregnancy by assessing common colds by self-report and using the common cold questionnaire (CCQ) and polymerase chain reaction (PCR) testing and retrospectively in early pregnancy and post partum.

Materials and Methods {#cesec10}
---------------------

### Study Design {#cesec20}

Pregnant women with and without asthma were recruited from April 2007 to November 2009 ([Fig 1](#fig1){ref-type="fig"} ) at the antenatal clinic of John Hunter Hospital, Newcastle, Australia. Written informed consent was obtained and ethics approval granted by the University of Newcastle and Hunter New England Area Health Service Research Ethics Committees (approval number 07/02/21/3.06). Women between 12 and 20 weeks\' gestation who were \> 18 years of age were included. Exclusion criteria were the presence of a chronic medical disease (other than asthma), drug or alcohol dependence, and an inability to attend study visits or perform spirometry. Control subjects had never received a diagnosis of asthma, whereas women with asthma had a doctor\'s diagnosis of asthma and asthma symptoms or therapy in the prior 3 months.Figure 1Recruitment, enrollment, and study completion. MAP = Managing Asthma in Pregnancy; RCT = randomized controlled trial.

Women completed monthly clinical visits and were telephoned fortnightly (e-Appendix 1, e-Fig 1). The majority (157 of 168, 93%) of the women with asthma also commenced participation in the Managing Asthma in Pregnancy (MAP) study.[@bib11], [@bib12] Regardless of coparticipation in MAP, all women, with and without asthma, had the same schedule of study visits and telephone contacts and were eligible for additional visits based on the same criteria (current common cold). Some women consented to donate blood for in vitro studies of responses to viral infection.[@bib8], [@bib9]

### Clinical Measures {#cesec30}

At each visit and telephone contact, asthma symptoms over the past 7 days were collected by self-report and using the Asthma Control Questionnaire (ACQ7).[@bib13] Exacerbations were assessed by direct questioning and defined as those requiring medical intervention (hospital admission, ED presentation, unscheduled doctor visit, or the use of oral corticosteroids).

Common colds were assessed by direct questioning (self-report: "Do you currently have a cold?") and using the CCQ (e-Fig 2)[@bib14] at each contact. The CCQ assessed nine symptoms over four domains (general: fevers, chills, muscle pains; nasal: watery eyes, runny nose, sneezing; throat: sore throat; chest: cough, chest pain), which were scored as none (0), mild (1), moderate (2), or severe (3).[@bib14] A cold was "probable" when symptoms were moderate in at least two domains or mild in at least three domains. Unless otherwise indicated, a common cold was defined as instances wherein the CCQ indicated a "probable cold." Common cold severity was assessed by the total CCQ score (possible score, 0-27) and by the proportion of colds with a score ≥ 10.[@bib14] Baseline scores are given in e-Table 1. Colds in early pregnancy and post partum were retrospectively assessed by self-report at the first study visit and 6 months post partum, respectively. Subjects with a current cold (women with and without asthma) or current asthma exacerbation were offered additional visits either at home or hospital within 48 h. If a new cold was reported 14 days after a previous report, it was considered a separate clinical event.[@bib7]

### Virus PCR Testing {#cesec40}

Nasal and throat swabs were collected from women with common colds. Viruses were identified using real-time quantitative PCR for rhinovirus, enterovirus, respiratory syncytial virus A and B, influenza A and B, coronavirus, and human metapneumovirus.[@bib15]

### Statistical Methods {#cesec50}

Statistical analysis was performed using Stata 11 (StataCorp LP). Results are presented as mean ± SD or median (interquartile range \[IQR\]) with Student *t* test and Wilcoxon rank sum tests as appropriate and Wilcoxon signed rank test for paired data. The χ^2^ test was used to compare proportions. Two-sided tests with *P* \< 05 were considered significant, with the exception of data on the frequency of common colds and PCR-positive colds (*P* \< .025, because this outcome was assessed by two similar methods). The rate difference between the groups for colds was compared using a Poisson regression model adjusted for BMI, atopy, and parity, with a robust option when data were overdispersed. Secondary outcomes were cold severity (analyzed as panel data using Stata\'s xtreg with random effects and adjusted for baseline CCQ score, BMI, atopy, and parity), impact of colds on asthma, and impact of colds on pregnancy outcomes. We assessed the relationship between PCR-positive colds in asthma and preeclampsia/pregnancy-induced hypertension with logistic regression, adjusting for smoking, parity, age, BMI, and multiple pregnancy. Receiver operator curve (ROC) analyses were used to evaluate different diagnostic cutoff levels for the CCQ score in PCR positive infections (e-Fig 3). Kaplan-Meier survival estimates were used to investigate the time to first cold (e-Fig 4).

Results {#cesec60}
-------

### Subject Characteristics {#cesec70}

Two hundred eighty-five pregnant women were recruited (168 with asthma, 117 control subjects) ([Fig 1](#fig1){ref-type="fig"}). Pregnant women with asthma had significantly higher BMI (*P* \< .002), significantly worse lung function (*P* \< .05), and were more likely to have atopy (*P* \< .0001) than control subjects ([Table 1](#tbl1){ref-type="table"} , e-Appendix 2, e-Table 2).Table 1Subject CharacteristicsCharacteristicControl Group (n = 117)Asthma Group (n = 168)*P* ValueMaternal age,[a](#tbl1fn1){ref-type="table-fn"} y29.6 (4.6)28.5 (5.6).086Range, 18-38Range, 18-43Gestational age at recruitment,[a](#tbl1fn1){ref-type="table-fn"}wk16.6 (2.3)16.9 (2.4).193Range, 12.6-21.3Range, 11.7-21.9Gravidity[b](#tbl1fn2){ref-type="table-fn"}2 (1, 2)2 (1, 3).010Parity[b](#tbl1fn2){ref-type="table-fn"}1 (0, 1)1 (0, 2).016Para 0[c](#tbl1fn3){ref-type="table-fn"}49 (41.9)56 (33.3).178Maternal atopy[c](#tbl1fn3){ref-type="table-fn"}51 (45.9)115 (71.9)\< .0001n = 111n = 160Maternal BMI[b](#tbl1fn2){ref-type="table-fn"}25.2 (22.8, 28.7)27.7 (24.4, 32.1).0005n = 116n = 165Smoking status... Never[c](#tbl1fn3){ref-type="table-fn"}66 (56.4)80 (47.6)... Ex[c](#tbl1fn3){ref-type="table-fn"}32 (27.4)52 (31.0)... Current[c](#tbl1fn3){ref-type="table-fn"}18 (15.4)35 (20.8).245 Smoking pack-y[b](#tbl1fn2){ref-type="table-fn"}3.0 (0.9, 6.0)4.0 (1.5, 7.0).070Prebronchodilator spirometryn = 117n = 142... FEV~1~[a](#tbl1fn1){ref-type="table-fn"}3.29 (0.42)2.96 (0.52)\< .0001 % Predicted FEV~1~[a](#tbl1fn1){ref-type="table-fn"}102.9 (11.1)93.8 (14.6)\< .0001 FVC[b](#tbl1fn2){ref-type="table-fn"}3.93 (3.52, 4.24)3.72 (3.34, 4.18).030 % Predicted FVC[b](#tbl1fn2){ref-type="table-fn"}107.6 (98.0, 116.2)103.0 (74.5, 112.6).037n = 116No ICS treatment[d](#tbl1fn4){ref-type="table-fn"}...120 (71.4)...ICS treatment[d](#tbl1fn4){ref-type="table-fn"}...15 (8.9)...ICS/LABA treatment[d](#tbl1fn4){ref-type="table-fn"}...33 (19.6)...ICS dose (among ICS users), BDP equivalents μg/d...800 (650, 1,000)...n = 47ACQ7...0.86 (0.29, 1.57)...Influenza vaccine for current season[c](#tbl1fn3){ref-type="table-fn"}10 (8.5)16 (9.5).8407[^1][^2][^3][^4][^5]

### Frequency of Common Colds During Pregnancy {#cesec80}

Pregnant women with asthma had more questionnaire-detected common colds during pregnancy (71%) than pregnant women without asthma (46%; *P* \< .0001; relative risk \[RR\], 1.83; 95% CI \[1.39, 2.41\]) ([Table 2](#tbl2){ref-type="table"} ). More women with asthma had multiple common colds than women without asthma (33% vs 16%; *P* = .0028; RR, 1.25; 95% CI \[1.09, 1.42\]). There were 223 common cold events in the asthma group and 83 in the control group (e-Table 3). The rate of common cold events adjusted for follow-up time, atopy, parity, and maternal BMI was significantly higher in the asthma group compared with the control group ([Fig 2](#fig2){ref-type="fig"} ) (incidence rate ratio \[IRR\], 1.77; 95% CI \[1.30, 2.42\]; *P* \< .0001). The control group had the same proportion of common colds detected in the second and third trimesters, whereas the asthma group had significantly more common colds detected in the second compared with the third trimester ([Table 2](#tbl2){ref-type="table"}) (P \< .0001), despite longer follow-up times for the third trimester. In addition to questionnaire-detected colds, women with asthma also self-reported more colds prospectively during pregnancy and retrospectively in early pregnancy and post partum (e-Table 4).Table 2Frequency of Common Colds During PregnancyCold MeasuresControl (n = 117)Asthma (n = 168)Effect Size*P* ValueSubjects with ≥ 1 cold (probable by CCQ) during pregnancy[a](#tbl2fn1){ref-type="table-fn"}54 (46)120 (71.4)RR, 1.83; 95% CI (1.39, 2.41)\< .0001Subjects with \> 1 common cold during pregnancy[a](#tbl2fn1){ref-type="table-fn"}19 (16.2)55 (32.7)RR, 1.25; 95% CI (1.09, 1.42).0028No. of colds per person[b](#tbl2fn2){ref-type="table-fn"}0 (0, 1)1 (0, 2)...\< .0001Range, 0-6Range, 0-8No. of common cold events/person-wk[c](#tbl2fn3){ref-type="table-fn"}0.0350.067IRR, 1.77; 95% CI (1.30, 2.42)\< .0001Cold events by season...... Summer[d](#tbl2fn4){ref-type="table-fn"}13 (15.7)33 (14.8) Autumn[d](#tbl2fn4){ref-type="table-fn"}24 (28.9)53 (23.8) Winter[d](#tbl2fn4){ref-type="table-fn"}26 (31.3)75 (33.6) Spring[d](#tbl2fn4){ref-type="table-fn"}20 (24.1)62 (27.8)[^6][^7][^8][^9][^10]Figure 2Cumulative common colds adjusted for total person-weeks per group in the asthma (△) and control (▴) groups over the course of pregnancy (\*incidence rate ratio, 1.77; 95% CI \[1.30, 2.42\]).

Nasal and/or throat swab samples were collected from 80% of common cold events (20% were not collected because of refusal by the participant or lack of a clinical visit at the time of the event), within a median time from symptom onset of 3.5 days (IQR, 3-7 days) in the control group and 4 days (IQR, 2-7 days) in the asthma group (e-Table 5). Thirty-one percent of women with asthma and 18.8% of women without asthma had one or more PCR-positive colds during pregnancy (RR, 1.18; 95% CI \[1.03, 1.34\], asthma vs control) ([Fig 3](#fig3){ref-type="fig"} , [Table 3](#tbl3){ref-type="table"} ), but this did not reach our significance level of *P* \< .025 (*P* = .0305). There were 26 PCR-positive cold events in the nonasthmatic control group and 60 PCR-positive cold events in the asthma group (e-Table 5). There was no significant difference in the rate of PCR-positive colds between groups (adjusted for follow-up time, atopy, parity, and maternal BMI; IRR, 1.18; 95% CI \[0.72, 1.94\]; *P* = .505) ([Table 3](#tbl3){ref-type="table"}). The number of second trimester PCR-positive colds was higher than the number of third trimester colds in the asthma group (*P* = .0442) but not in the control group (*P* = .4524) (e-Table 5). In addition to questionnaire-detected colds, women with asthma also self-reported more colds prospectively during pregnancy and retrospectively in early pregnancy and post partum (e-Table 4).Figure 3Cumulative polymerase chain reaction-positive colds adjusted for total person-weeks per group in the asthma (△) and control (▴) groups over the course of pregnancy (incidence rate ratio, 1.18; 95% CI \[0.72, 1.94\]).Table 3Frequency of PCR-Positive Colds During PregnancyCold MeasuresControl (n = 117)Asthma (n = 168)Effect Size*P* ValueSubjects with ≥ 1 PCR-positive cold[a](#tbl3fn1){ref-type="table-fn"}22 (18.8)52 (31.0)RR, 1.18; 95% CI (1.03, 1.34).0305Subjects with multiple PCR-positive cold events[a](#tbl3fn1){ref-type="table-fn"}3 (2.6)8 (4.8)....5254PCR colds per person-weeks[b](#tbl3fn2){ref-type="table-fn"}0.01080.0182IRR, 1.18; 95% CI (0.72, 1.94).505Influenza A[c](#tbl3fn3){ref-type="table-fn"}1 (3.4)5 (7.7)......Influenza B[c](#tbl3fn3){ref-type="table-fn"}2 (6.9)3 (4.6)......Human RV[c](#tbl3fn3){ref-type="table-fn"}13 (44.8)25 (38.5)......Human EV[c](#tbl3fn3){ref-type="table-fn"}1 (3.4)6 (9.2)......CoV[c](#tbl3fn3){ref-type="table-fn"}3 (10.3)9 (13.8)......RSV A[c](#tbl3fn3){ref-type="table-fn"}0 (0)1 (1.5)......RSV B[c](#tbl3fn3){ref-type="table-fn"}4 (13.8)1 (1.5)......Human MPV[c](#tbl3fn3){ref-type="table-fn"}5 (17.2)15 (23.1)......Total viruses detected2965......Multiple infectionRV + MPVRV + EV......RSV B + MPVRV + CoV......RSV B + MPVCoV + MPV.........RSVA + RV.........FluA + MPV......[^11][^12][^13][^14]

### Severity of Common Colds During Pregnancy {#cesec90}

The median total CCQ score was higher among common cold events in the asthma group (median, 8; IQR \[5, 10\]) compared with the control group (median, 6; IQR \[5, 8\]) and was statistically significant when baseline values were adjusted for (xtreg, coefficient 1.16; 95% CI \[0.11, 2.21\]; *P* = .031) (e-Table 6). However, in PCR-positive colds, the total CCQ score was not different between groups (e-Table 6) (xtreg, coefficient 0.86; 95% CI \[−1.13, 2.85\]; *P* = .397).

### Impact of Colds on Asthma {#cesec100}

One-third of the PCR-positive viral infections were associated with exacerbation requiring medical intervention and a further one-third with loss of control (e-Tables 7, 8). Total CCQ score significantly correlated with ACQ score (Spearman *r* = 0.3187, *P* = .0131, Spearman rank correlation) (e-Fig 5).

Among the subgroup of women with asthma participating in the MAP study, those randomized to fractional exhaled nitric oxide-based management (n = 69) were significantly less likely to report common colds (63.8% vs 82.2%; RR, 0.492; 95% CI \[0.274, 0.881\]) or PCR-positive colds (23.2% vs 42.5%; RR, 0.749; 95% CI \[0.592, 0.948\]) compared with those randomized to clinical guidelines-based management (n = 73).

### Impact of Colds on Neonatal Outcomes {#cesec110}

In the control group, women with at least one PCR-positive cold had babies of significantly lower birth weight (*P* = .0274) and length (*P* = .0236) compared with control subjects with PCR-negative colds ([Table 4](#tbl4){ref-type="table"} ). Women with asthma with PCR-positive colds had significantly increased odds of preeclampsia or pregnancy-induced hypertension when adjusted for known preeclampsia risk factors (maternal smoking, age, BMI, parity, multiple pregnancy; OR, 8.48; 95% CI \[1.41, 51.11\]; *P* \< .02) ([Table 4](#tbl4){ref-type="table"}) compared with women with asthma with PCR-negative colds.Table 4Impact of PCR-Positive Colds on Pregnancy Outcomes in the Control Group and the Asthma GroupControl GroupAsthma GroupPregnancy OutcomesPCR− Colds (n = 24 Pregnancies and Babies)PCR+ Colds (n = 22 Pregnancies and Babies)*P* ValuePCR− Colds (n = 53 Pregnancies, n = 55 Babies)PCR+ Colds (n = 52 Pregnancies, n = 52 Babies)*P* ValueGestational age,[a](#tbl4fn1){ref-type="table-fn"} wk40.8 (39.7, 41.3)39.9 (38.7, 41.0).155539.9 (38.6, 40.5)39.6 (38.4, 40.3).6265n = 22n = 22n = 54n = 52Preterm delivery of infant (\< 37 completed wk)[b](#tbl4fn2){ref-type="table-fn"}0 of 223 of 22 (13.6).23169 of 54 (16.7)4 of 52 (7.7).2661Birth weight,[a](#tbl4fn1){ref-type="table-fn"} g3,600 (3,384, 3,885)3,130 (2,790, 3,673).02743,520 (3,180, 3,875)3,280 (3,010, 3,520).0605n = 22n = 22n = 51n = 51Low birth weight (\< 2,500 g)[b](#tbl4fn2){ref-type="table-fn"}0 of 224 of 22 (18.2).11575 of 51 (9.8)4 of 51 (7.8).727Birth length,[a](#tbl4fn1){ref-type="table-fn"} cm52 (51.5, 53.5)51 (49, 51.9).023651 (49, 53)50.5 (49, 52).2622n = 15n = 18n = 45n = 44Birth head circumference,[a](#tbl4fn1){ref-type="table-fn"} cm34.5 (33.5, 35.5)34 (33, 35).097434.5 (33.5, 35.4)34 (33, 35).3348n = 21n = 20n = 51n = 51Apgar at 1 min[a](#tbl4fn1){ref-type="table-fn"}9 (8, 9)8 (8, 9).53289 (7, 9)9 (6, 9).8501n = 21n = 21n = 50n = 51Apgar at 5 min[a](#tbl4fn1){ref-type="table-fn"}9 (9, 9)9 (9, 9).55619 (9, 9)9 (9, 9).4819n = 22n = 22n = 50n = 51Maternal preeclampsia[b](#tbl4fn2){ref-type="table-fn"}01 (4.5).317706 (11.5).0355Maternal pregnancy-induced hypertension[b](#tbl4fn2){ref-type="table-fn"}01 (4.5).31772 (3.8)5 (9.6).4338Maternal gestational diabetes00...2 (3.8)4 (7.7).6741Still birth00...1 (1.9)0.3241Neonatal intensive care admission[b](#tbl4fn2){ref-type="table-fn"}3 (13.6)2 (9).63488 (4.8)7 (13.5).8416Congenital anomaly[b](#tbl4fn2){ref-type="table-fn"}01 (4.5).317700...[^15][^16][^17]

Discussion {#cesec120}
----------

Pregnant women with asthma have more common colds during pregnancy than pregnant women without asthma, both by self-report and questionnaire. The severity of symptoms was higher in subjects with asthma with common colds than control subjects, when adjusted for baseline differences. Although PCR-positive colds were of similar severity in the two groups, virus-confirmed colds in subjects with asthma frequently resulted in exacerbations and were associated with perinatal effects.

Previous studies in nonpregnant adults with asthma have suggested that subjects with asthma are no more susceptible to respiratory tract infections than subjects without asthma.[@bib7] The evidence in the present study suggests that in pregnancy, women with asthma may be more susceptible to common colds than women without asthma but that cold symptoms associated with PCR-positive colds are similar to those in women without asthma. In a large prospective study, 14.4% of women had a common cold during pregnancy, with one-half of these colds medically recorded.[@bib16] The CCQ we used identified more common colds than self-report, and not all of these were virus-positive by laboratory testing. The prospective nature of our study likely contributed to a high rate of reporting of common colds. It is possible that confounding by symptoms of rhinitis may have contributed to a high proportion of women with questionnaire-detected colds.

Common colds were more likely to occur in the second trimester than the third trimester in the asthma group only. Bánhidy et al[@bib16] found that there was a lower prevalence of the common cold in the eighth and ninth months of pregnancy compared with the first 7 months; however, it was unclear if follow-up time and early deliveries had been accounted for. Asthma exacerbations also peak in the late second trimester.[@bib5], [@bib17] Further evidence is required to determine if this is due to a pregnancy-specific rise in susceptibility to infection.

One-third of PCR-positive colds were associated with exacerbations requiring medical intervention. In previous studies, 60% of cases with a positive virus identification were associated with asthma exacerbation,[@bib18] whereas cold severity was predictive of subsequent asthma worsening.[@bib19] Viral infection is a significant asthma trigger, possibly because of the inflammatory pathways activated during infection. Understanding the relationship between viral infection and asthma[@bib20] is important, as preventing viral infection could also prevent exacerbations. We have evidence that improved asthma management through fractional exhaled nitric oxide monitoring is associated with a reduction not only in exacerbations[@bib11] but also in PCR-positive viral infections.

Pregnant women with asthma who had PCR-positive colds were more likely to have preeclampsia than women without PCR-positive colds, consistent with studies suggesting an association between maternal infection (bacterial or viral) and the risk of preeclampsia, possibly due to changes in the maternal immune system.[@bib21] Pregnant women with asthma are at increased risk of preeclampsia compared with pregnant women without asthma.[@bib22], [@bib23], [@bib24], [@bib25] No previous reports have linked asthma, preeclampsia, and viral infection during pregnancy. It is possible that inflammation associated with the response to viral infection and/or asthma exacerbation may contribute to the underlying endothelial dysfunction in preeclampsia.

There are limitations to our study. The CCQ is an unvalidated tool, which limits the conclusions we can make using this instrument, particularly since the CCQ is not validated to distinguish between viral infections and rhinitis. There was the possibility of recall bias for colds assessed retrospectively, although for the majority of pregnancy we collected data prospectively. The pregnant women with asthma had higher parity than pregnant women without asthma, which might increase their exposure to virus infections from other children.[@bib26], [@bib27] However, we adjusted for this as well as other confounders, such as atopy and BMI (a known risk factor for exacerbations in pregnancy[@bib28]), when considering the rate of colds. Our sample collection time was not ideal, with swabs collected within a median of 3 to 4 days from symptom worsening. We contacted women fortnightly by phone and sent mobile phone text reminders every other week to try to increase participation and offered home visits during colds. The CCQ covers only 2 days of the past 14, and since we did not administer it daily, it is possible colds were missed. The number of PCR-positive colds experienced by women with asthma, when adjusted for follow-up time, was not significantly different from the control group. This may be due to a lack of power, since only a proportion of common colds were tested in the laboratory, or rhinitis-like symptoms and cough may be amplified by asthma or pregnancy themselves, resulting in more colds being detected that were not true infections. Although we found second trimester colds to be more frequent than third trimester colds, it is possible that rhinitis of pregnancy may have contributed to this finding.

Conclusions {#cesec130}
-----------

Common colds were more frequently reported among pregnant women with asthma compared with women without asthma. They occurred more often in the second trimester than the third, perhaps explaining the greater exacerbation risk at this time. There was an impact on maternal health, with one-third of infections associated with exacerbations requiring medical intervention. Prevention of respiratory viral infections may improve asthma outcomes during pregnancy.

Web Extra Material {#cesec140}
==================
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[^1]: Data were collected at the first study visit. ACQ7 = Asthma Control Questionnaire (7 item); BDP = beclomethasone dipropionate; ICS = inhaled corticosteroid; IQR = interquartile range; LABA = long-acting β-agonist.

[^2]: Mean (SD), Student *t* test.

[^3]: Median (IQR), Wilcoxon rank sum test.

[^4]: No. (%), χ^2^ test.

[^5]: No. (%).

[^6]: Seasons were Australian summer (December-February), autumn (March-May), winter (June-August), spring (September-November). CCQ = common cold questionnaire; IRR = incidence rate ratio; RR = relative risk. See [Table 1](#tbl1){ref-type="table"} legend for expansion of other abbreviation.

[^7]: No. (%), χ^2^ test, RR.

[^8]: Median (IQR), Mann-Whitney test.

[^9]: IRR, Poisson regression, adjusted for atopy, parity, and BMI.

[^10]: No. (%).

[^11]: CoV = coronavirus; EV = enterovirus; FluA = influenza A; MPV = metapneumovirus; PCR = polymerase chain reaction; RSV = respiratory syncytial virus; RV = rhinovirus. See [Table 1](#tbl1){ref-type="table"} legend for expansion of other abbreviations.

[^12]: No. (%), χ^2^ test, RR.

[^13]: IRR, Poisson regression adjusted for atopy, parity, and BMI.

[^14]: No. (% of all viruses detected).

[^15]: Note: Data not available on all infants due to delivery at other hospitals. See [Table 1](#tbl1){ref-type="table"}, [Table 3](#tbl3){ref-type="table"} legends for expansion of abbreviations.

[^16]: Median (IQR) Wilcoxon rank sum test.

[^17]: No. (%), χ^2^ test.
